---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-038728"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:27:43.035073+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports Q4 2024 net loss $6.2M; cash $11.1M as of Dec 31; clinical updates on INB-100/200/400

## Summary
- Net loss Q4 2024 $6.2M ($0.08/share) vs $7.6M ($0.22/share) in Q4 2023; full-year net loss $30.4M vs $30.0M.
- Cash $11.1M as of Dec 31, 2024; plus $4.1M net proceeds from ATM/warrant exercises in Feb 2025, extending runway into March 2026.
- INB-100 Phase 1: 100% of treated AML patients relapse-free as of Jan 17, 2025; no CRS/ICANS; enrollment expansion ongoing.
- INB-200: majority of patients exceeded expected PFS; one IDH-mutant patient progression-free for 40.5 months as of Oct 2024.
- INB-400 Phase 2 enrollment paused; seeking partnerships; introduced INB-600 platform (INB-619 TCE targeting CD19) with preclinical data.

## SEC filing metadata
- accession: 0000950170-25-038728
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017025038728/0000950170-25-038728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017025038728/inab-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-038728
- JSON: https://secwatch.observer/filing/0000950170-25-038728.json
- Plain text: https://secwatch.observer/filing/0000950170-25-038728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.